4.60

1.92% -0.09

After Hours: 4.61 0.01 +0.22%

Lexeo Therapeutics Inc (LXEO)

Overview News Price History Financials Discussions Forecast

Lexeo Therapeutics Inc stock is traded at $4.60, with a volume of 696.07K. It is down -1.92% in the last 24 hours and up +5.26% over the past month. Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Previous Close:

$4.69

Open:

$4.69

24h Volume:

696.07K

Relative Volume:

0.77

Market Cap:

$361.20M

Revenue:

$531.00K

Net Income/Loss:

$-99.96M

P/E Ratio:

-2.0986

EPS:

-2.1919

Net Cash Flow:

$-98.96M

1W Performance:

-4.37%

1M Performance:

+5.26%

6M Performance:

-51.63%

1Y Performance:

+3.37%

1-Day Range:

$4.525

$4.756

1-Week Range:

$4.33

$4.88

52-Week Range:

$3.60

$10.99

Lexeo Therapeutics Inc Stock (LXEO) Company Profile

Name

Lexeo Therapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(212) 547-9879

Address

345 PARK AVENUE SOUTH, NEW YORK

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

LXEO's Discussions on Twitter

Compare LXEO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LXEO Lexeo Therapeutics Inc	4.60	365.52M	531.00K	-99.96M	-98.96M	-2.1919
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Initiated	Raymond James	Strong Buy
Nov-20-25	Initiated	Cantor Fitzgerald	Overweight
Oct-15-25	Initiated	Guggenheim	Buy
Jul-31-25	Initiated	Oppenheimer	Outperform
Jun-13-24	Initiated	Robert W. Baird	Outperform
Jun-06-24	Initiated	H.C. Wainwright	Buy
Nov-28-23	Initiated	Chardan Capital Markets	Buy
Nov-28-23	Initiated	JP Morgan	Overweight
Nov-28-23	Initiated	Leerink Partners	Outperform
Nov-28-23	Initiated	RBC Capital Mkts	Outperform
Nov-28-23	Initiated	Stifel	Buy

View All

Lexeo Therapeutics Inc Stock (LXEO) Latest News

Jul 01, 2026

Lexeo Therapeutics CMO sells $98,592 in shares - Investing.com

Jul 01, 2026

Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock - Investing.com

Jul 01, 2026

Form 4 Lexeo Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

Lexeo Therapeutics CMO sells $98,592 in shares By Investing.com - Investing.com Canada

Jul 01, 2026

RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer - Stock Titan

Jul 01, 2026

Lexeo Therapeutics (LXEO) COO reports stock award and small tax-related sale - Stock Titan

Jul 01, 2026

Lexeo Therapeutics (LXEO) CMO awarded 55K shares and sells 22K to cover RSU taxes - Stock Titan

Jul 01, 2026

Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale - Stock Titan

Jul 01, 2026

LXEO (NASDAQ) Form 144: Proposed resale of 4,666 vested shares via Fidelity - Stock Titan

Jul 01, 2026

[144] Lexeo Therapeutics, Inc. SEC Filing - Stock Titan

Jul 01, 2026

LXEO (NASDAQ: LXEO) director files Form 144 proposing sale of 25,947 shares - Stock Titan

Jul 01, 2026

5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey

Jul 01, 2026

Jun 29, 2026

Form 4 Lexeo Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Lexeo Shareholders Reelect Directors, Ratify KPMG Auditor - TipRanks

Jun 29, 2026

Lexeo Therapeutics (NASDAQ: LXEO) investors approve directors and ratify KPMG auditor - Stock Titan

Jun 29, 2026

Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70 - Stock Titan

Jun 29, 2026

Lexeo Therapeutics (LXEO) director receives 35,000 options at $4.70 - Stock Titan

Jun 29, 2026

Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 - Stock Titan

Jun 29, 2026

Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 strike - Stock Titan

Jun 29, 2026

Lexeo Therapeutics (LXEO) director receives grant of 35,000 stock options at $4.70 - Stock Titan

Jun 29, 2026

Jun 26, 2026

Price to earnings forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView

Jun 25, 2026